CCR2 and familial pancreatic carcinoma: Consistent with this, ongoing clinical trials have reported encouraging results of CCR2 inhibitors, especially as combination therapies, in patients with pancreatic cancers, hepatocellular carcinomas and ovarian cancers [37].